IAV 001
Alternative Names: IAV-001Latest Information Update: 28 Dec 2021
At a glance
- Originator Aegis Life
- Class Influenza virus vaccines; Nucleic acids
- Mechanism of Action DNA modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 28 Dec 2021 IAV 001 is available for licensing as of 28 Dec 2021. https://aegis.life/
- 01 Dec 2021 Preclinical trials in Influenza virus infections in USA (Parenteral) before December 2021 (Aegis Life pipeline, December 2021)